Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden

Summary

This retrospective observational cohort study aims to describe the impact of COVID-19 in patients treated with autologous stem cell transplantation (ASCT) for malignant disease in terms of risk factors, morbidity, need for supportive care and mortality. All patients treated with ASCT in Sweden from 1st January 2020 until 31st December 2020 are eligible for this study. Patients who also has tested positive for SARS-CoV-2 from start of conditioning or later will be identified through the national registry of the Public Health Agency of Sweden and a systematic analysis of their medical records will be performed.

Conditions

• Covid19
• Myeloma Multiple
• Malignant Lymphoma
• Hematologic Neoplasms
• Stem Cell Transplant Complications

Interventions

OTHER

Autologous stem cell transplantation

The study will describe the implications of COVID-19 infection following autologous stem cell transplantation

Sponsors & Collaborators

• Karolinska University Hospital

  collaborator OTHER

• Sahlgrenska University Hospital

  collaborator OTHER

• Lund University Hospital

  collaborator OTHER

• University Hospital, Linkoeping

  collaborator OTHER

• University Hospital, Umeå

  collaborator OTHER

• Region Örebro County

  collaborator OTHER

• Uppsala University Hospital

  collaborator OTHER

• Uppsala University

  lead OTHER

Principal Investigators

• Honar Cherif, MD, Ass prof · Department of Medical Sciences, Uppsala University

• Thomas Silfverberg, MD · Center for Clinical Research Dalarna and Department of Medical Sciences-Uppsala University

• Kristina Carlson, MD, Ass Prof · Department of Medical Sciences, Uppsala University

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-01

Primary Completion

2021-08-30

Completion

2021-12-31

Countries

• Sweden

Study Locations